Published: January 31, 2023
Last updated: August 17, 2023
GBI’s CSO, Muctarr Sesay, has participated in Pharma Almanac’s roundtable discussions.
The topic of the discussion was “What do you view as the most disruptive or transformational technology or development on the horizon?”
Dr. Sesay added, “The nuclear theranostics approach has sparked increasing interest and gained importance in parallel to the growth in molecular imaging and personalized medicine, thereby facilitating the customized management for various diseases.”
Click here to read the full article!
